TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06427473

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary program
Description: Participants will attend 8-week online dietary course. In addition to weekly classes, participants are required to photograph each meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary program
Description: Participants will attend 8-week online dietary course. In addition to weekly classes, participants are required to photograph each meal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Everyday walking steps more than 4000 steps. To accurately track participants' daily step counts, the research team provided quailfied pedometers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Everyday walking steps more than 4000 steps. To accurately track participants' daily step counts, the research team provided quailfied pedometers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness program
Description: Participants will attend 8-week online mindfulness course. In addition to weekly classes, participants practiced mindfulness individually for 5 minutes each day and maintained a mindfulness diary.
Study: NCT04187950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with B. lactis and added honey
Description: The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt with heat-inactivated B. lactis and added cane sugar
Description: The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
Study: NCT04716829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUNA-EMG
Description: The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot allows the adaptation of movements during rehabilitation sessions according to the individually generated strength.
Study: NCT06289140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pterostilbene cocrystal (ccPT) - Gelatin capsule
Description: Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
Study: NCT05844423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 ml dose of 1.1 mcg VAX-24
Description: 24 valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 ml dose of PCV20
Description: 20 valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 ml dose of 2.2 mcg VAX-24
Description: 24 valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 ml dose of 2.2/4.4 mcg VAX-24
Description: 24 valent pneumococcal conjugate vaccine
Study: NCT06518499

Intervention type: PROCEDURE
Intervention: Pilonidal sinus surgery
Description: Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure

Intervention type: PROCEDURE
Intervention: Pilonidal sinus surgery
Description: Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure

Intervention type: PROCEDURE
Intervention: Pilonidal sinus surgery
Description: Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure
Study: NCT05954871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-1971
Description: GDC-1971 capsules or tablets will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-1971
Description: GDC-1971 capsules or tablets will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-1971
Description: GDC-1971 capsules or tablets will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-1971
Description: GDC-1971 capsules or tablets will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib tablets will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib tablets will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab, solution for infusion will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab, solution for infusion will be administered as specified in each treatment arm.
Study: NCT05974826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the SI! Program for Secondary Schools (NCT03504059)
Description: The SI! Program is implemented from 1st to 4th grade of Secondary Schools. A total of 12 hours of classroom intervention per academic year, organized through three educational units, and with active and participative methodologies, and complementary intervention in the family setting, at school and on teachers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Fifty-Fifty Program (NCT02367963)
Description: 1. Training stage: the focus is on improving individual health, through workshops (given in person by experts), and on the challenges of changing habits supervised and supported by the SHE Foundation~2. Peer-to-peer support group sessions: It is designed to make the subjects participate actively in their healthcare. Along the sessions subjects propose assumable health goals. Participants will be able to view videos with key messages from the workshops to continue the sustainability of the changes made, and the development of new ones. Peer-to-peer support group sessions have two phases: a) leaders will receive support from the Foundation; b) participants will become agents of change with the people around them, and also in their municipality with specific actions to promote health. The role of Foundation's will only be to monitor and resolve possible doubts.
Study: NCT04950751

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: candidate vaccine, SCB-2020S
Description: a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: candidate vaccine, SCB-2020S
Description: a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: candidate vaccine, SCB-2020S
Description: a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
Study: NCT05604586

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
Study: NCT04950751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: candidate vaccine, SCB-2020S
Description: a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: candidate vaccine, SCB-2020S
Description: a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
Study: NCT06022809

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dada Kwa Dada (individual-level)
Description: Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DADA (group-level)
Description: DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.
Study: NCT05986487

Intervention type: DEVICE
Intervention: CPAP or usual practice
Description: CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.

Intervention type: DEVICE
Intervention: Monitoring and intervention in follow-up
Description: Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.

Intervention type: DEVICE
Intervention: Monitoring and intervention in follow-up
Description: Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
Study: NCT04606264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial Analgesia
Description: This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial Analgesia
Description: This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial Analgesia
Description: This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block 1: Paravertebral
Description: This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block 1: Paravertebral
Description: This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: This randomized group will receive 8 mg of perphenazine orally preoperatively.
Study: NCT05695027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary supplements - Nicotinamide and Pyruvate
Description: Nutritional supplements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06365502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical treatment
Description: All individuals will receive guideline-directed medical treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-directed medical treatment
Description: All individuals will receive guideline-directed medical treatment.
Study: NCT06563804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S227928
Description: For administration via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S227928
Description: For administration via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S227928
Description: For administration via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S227928
Description: For administration via intravenous (IV) infusion
Study: NCT05307289

Intervention type: OTHER
Group type: OTHER
Intervention: Biposy
Description: Biopsy at inclusion visit and at disease progression if applicable
Study: NCT05185882

Intervention type: OTHER
Intervention: Single leg squat
Description: Single leg squat exercise in different circumstances
Study: NCT04711252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Dosage formulation: AZD9833 tablets will be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Dosage formulation: Anastrozole tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole placebo
Description: Dosage formulation: anastrozole placebo tablets will be administrated orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9833 placebo
Description: Dosage formulation: AZD9833 placebo tablets will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dosage formulation: palbociclib tablets/capsules will be administered orally
Study: NCT06563804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: For oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: For oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: For oral administration
Study: NCT05119335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral NKT2152
Description: Oral HIF2α inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral NKT2152
Description: Oral HIF2α inhibitor
Study: NCT05558267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Table Salt
Description: Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Table Salt
Description: Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt Substitute
Description: Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt Substitute
Description: Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
Study: NCT05303857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector
Description: Injection of the semaglutide once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo once weekly
Study: NCT05338320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Erector Spinae Plane Block
Description: General anesthesia and Ultrasound Guided Erector Spinae Plane Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: General anesthesia and intrathecal morphine

Intervention type: OTHER
Group type: OTHER
Intervention: General anesthesia using intravenous fentanyl (1µg/kg)
Description: General anesthesia using intravenous fentanyl (1µg/kg)
Study: NCT06433921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-152a
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
Study: NCT06289140

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pterostilbene free form (PT)
Description: Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule
Description: Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).
Study: NCT04606264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: This randomized group will receive 8 mg of perphenazine orally preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: This randomized group will receive 40 mg of aprepitant orally preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate
Description: This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: This randomized group will receive 4 mg of ondansetron orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: This randomized group will receive 4 mg of ondansetron orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: This randomized group will receive 4-5 mg of dexamethasone intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: This randomized group will receive 4-5 mg of dexamethasone intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block 2: QL1
Description: This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block 2: QL1
Description: This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
Study: NCT06411145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXERVATE® 0.002%
Description: Cenegermin-bkbj (20 mcg/mL) is an ophthalmic solution contained in a multiple-dose vial. The topical drops are administered 6 times/day for a 8-week course.
Study: NCT06197672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4CAR
Description: CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
Study: NCT04746859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention Visit
Description: Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.

Intervention type: OTHER
Group type: OTHER
Intervention: Prevention Visit
Description: Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer health coaching
Description: Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
Study: NCT05349877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
Study: NCT04711252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Dosage formulation: palbociclib tablets/capsules will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist
Description: Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist
Description: Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Study: NCT06550024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SakuraBead Resorbable Microspheres
Description: Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroid injection in the knee